not by increased levels of LDL-C have been associated with HAART (1). Insulin resistance, impaired glucose tolerance, impaired fasting glucose and diabetes mellitus are glucose metabolism disorders also reported in persons with HIV infection with and without HAART (2). The exact etiologic mechanisms for development of these disorders are still uncertain because not all of the patients exposed to the same HAART regimens are similarly affected. Alterations in acute phase response proteins in response to acute or chronic inflammation and
Background: Although an increasing access to ART in sub-Saharan Africa has made it possible for HIV/AIDS patients to live longer, clinicians managing such patients are faced with the challenge of drug-related metabolic complications.
Methods: A cross -sectional study was carried out at the University of Calabar Teaching Hospital, Nigeria, on three groups of participants; namely HIV patients on ART, ART-naïve patients and HIV negative subjects (n =75). Demographic and anthropometric data were collected using a well-structured questionnaire while biochemical parameters were measured using colorimetric methods.
Results: The highest prevalence of MS was associated with the HIV/AIDS patients on ART (i.e. 32.0 %, and 50.3% for NCEP-ATP III and IDF criteria respectively). Patients on ART had significant increases (p< 0.05) in waist to hip ratio, FPG, serum TG and LDL-c; and a significantly higher (p< 0.05) prevalence of hypertension, diabetes, low HDL-c and hypertriglyceridaemia compared to the ART-naïve patients. Low serum HDL-c was the most prevalent form of dyslipidaemia in allthree groups and the most prevalent component of MS in HIV patients.
Conclusion: ART increases the risk of MS and CVD. HIV/AIDS patients on ART should be advised on lifestyle modifications and undertake regular assessment of their cardiovascular risk factors.
Keywords: HIV/AIDS patients; antiretroviral therapy; ART-Naïve patients; Calabar Teaching Hospital; Calabar; Nigeria.
Background: Adiponectin has been associated with insulin resistance and dyslipidemia in Type 2 diabetes, though the mechanism of association is still uncertain. The adiponectin levels and lipid profile in relation to glycemic control were investigated in type 2 diabetics. Methods: Forty two diabetic subjects (35-64 years) and 33 age-matched non-diabetic subjects were recruited into this case control study. Socio-demographic characteristics, anthropometric indices and blood pressure were obtained. Total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein, (HDL), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) were estimated using colorimetric methods, atherogenic index (AI) was calculated, while serum adiponectin was determined by ELISA method. Results: Adiponectin levels of type 2 diabetics were not significantly different from the non-diabetics studied (p>0.05). Higher TG levels were observed in diabetics with poor glycemic control compared with those with good glycemic control (p<0.05). Hypertensive diabetics have higher TC and lower HDL-C levels compared with non hypertensive diabetics (p<0.05). Adiponectin correlated positively with HDL-C (r = 0.739, p = 0.01) and negatively with AI (r = -0.539, p = 0.001) only in the non diabetic group. No significant differences were observed in the adiponectin levels in relation with gender, duration of diabetes and glycemic state (p>0.05). Conclusion: Type 2 diabetics do not have lower adiponectin levels. Gender, duration of diabetes and glycemic control does not seem to exert any influence on adiponectin levels in type 2 diabetes. Adiponectin may be associated with reduced risk of atherosclerosis through its effects on HDL cholesterol metabolism. [Int J Res Med Sci 2013; 1(4.000): 563-570
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations –citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.